ARIX BIOSCIENCE PLC Unaudited NAV for April
Transparency directive : regulatory news
|
Arix Bioscience PLC (ARIX)
PRESS RELEASE Arix Bioscience plc
Unaudited NAV for April
LONDON, 11 May 2022: Arix Bioscience plc (“Arix” or the “Company”) (LSE: ARIX), a global venture capital company focused on investing in breakthrough biotechnology companies, announces the unaudited NAV of the Company for date ended 30 April 2022 as follows:
[ENDS]
Enquiries For more information on Arix, please contact:
Arix Bioscience plc +44 (0)20 7290 1050
Powerscourt Group Sarah MacLeod, Ibrahim Khalil, Nick Johnson +44 (0)20 7250 1446
About Arix Bioscience plc Arix Bioscience plc is a global venture capital company focused on investing in breakthrough biotechnology companies around cutting-edge advances in life sciences.
We collaborate with exceptional entrepreneurs and provide the capital, expertise and global networks to help accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors. www.arixbioscience.com
|
||||||||||||||||||
| ISIN: | GB00BD045071 |
| Category Code: | NAV |
| TIDM: | ARIX |
| LEI Code: | 213800OVT3AHQCXNIX43 |
| OAM Categories: | 3.1. Additional regulated information required to be disclosed under the laws of a Member State |
| Sequence No.: | 160805 |
| EQS News ID: | 1348823 |
| End of Announcement | EQS News Service |
|
|